New hand health survey for scleroderma patients tested in turkish
NCT ID NCT06658483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checks if a questionnaire called the Hand ScleroDerma Lived Experience Scale (HAnDE Scale) works well for Turkish-speaking people with systemic sclerosis. Researchers will ask 54 participants to fill out the survey and perform hand movement tests. The goal is to make sure the questions accurately measure hand problems in this group, which could help doctors better understand and treat hand issues in scleroderma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could provide a reliable tool for Turkish-speaking doctors to measure hand problems in scleroderma patients, improving care and research.
- What could go wrong
- This is a small, early-stage validation study, not a treatment trial. The questionnaire may not capture all hand issues or work well in other groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAND FUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inonu University
Malatya, Malatya, Turkey (Türkiye)
-
Pamukkale University
Denizli, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Can a new pill ease the hardening skin of systemic sclerosis?
- A drug after transplant may stop scleroderma from coming back
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.